QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Solid Tumor. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB). The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets. Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations. "
Primary outcome measures
- Number of targeted molecular alterations [Time frame: at day 0]
Secondary outcome measures (1)
- Number of patients eligible for targeted therapy (clinical trials or "off-label" drug) [Time frame: at day 0]
Eligibility criteria
Inclusion criteria
- Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;
- no standard or curative treatment available;
- non-opposition of the patient collected.
Exclusion criteria
- multiple cancer patient;
- ECOG Scale of Performance Status (PS) ≥2
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU de Nice — Nice
Identifiers
NCT: NCT04762862 · 21LGTS01